Association of expedited review programmes with postmarketing safety events of new drugs approved by the US food and drug administration between 2007 and 2017
Objective To explore the associations between the risks of postmarketing safety events of new drugs and the four expedited programmes of priority review, accelerated approval, fast track and breakthrough therapy established by the US Food and Drug Administration (FDA); and to investigate whether mul...
Saved in:
Main Authors: | Bao Liu, Xingyue Zhu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2022-07-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/12/7/e058843.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of postmarketing neuropsychiatric adverse events of avapritinib based on the FDA adverse event reporting system
by: Wei Mao, et al.
Published: (2025-01-01) -
Racial and gender disparities in the effect of new drug approvals on U.S. cancer mortality
by: Frank Lichtenberg
Published: (2024-02-01) -
Patient Safety Events Related to the Placement of Drug-Eluting Stents
by: Patient Safety Authority
Published: (2023-12-01) -
Pantoprazole – safety in drug-drug interaction
by: E. V. Shikh, et al.
Published: (2012-09-01) -
Approved antibacterial drugs in the last 10 years: from the bench to the clinic
by: Miguel García-Castro, et al.
Published: (2023-06-01)